article: SECTION 1. SHORT TITLE. This Act may be cited as the ``Commit to Opioid Medical Prescriber Accountability and Safety for Seniors Act'' or the ``COMPASS Act''. SEC. 2. MEDICARE NOTIFICATIONS TO OUTLIER PRESCRIBERS OF OPIOIDS. Section 1860D-4(c)(4) of the Social Security Act (42 U.S.C. 1395w- 104(c)(4)) is amended by adding at the end the following new paragraph: ``(D) Outlier prescriber notification.-- ``(i) Notification.--Beginning not later than two years after the date of the enactment of this subparagraph, the Secretary shall, in the case of a prescriber identified by the Secretary under clause (ii) to be an outlier prescriber of opioids, provide, subject to clause (iv), an annual notification to such prescriber that such prescriber has been so identified and that includes resources on proper prescribing methods and other information specified in accordance with clause (iii). ``(ii) Identification of outlier prescribers of opioids.-- ``(I) In general.--The Secretary shall, subject to subclause (III), using the valid prescriber National Provider Identifiers included pursuant to subparagraph (A) on claims for covered part D drugs for part D eligible individuals enrolled in prescription drug plans under this part or MA-PD plans under part C and based on the threshold established under subclause (II), conduct an analysis to identify prescribers that are outlier opioid prescribers for a period specified by the Secretary. ``(II) Establishment of threshold.--For purposes of subclause (I) and subject to subclause (III), the Secretary shall, after consultation with stakeholders, establish a threshold, based on prescriber specialty and geographic area, for identifying whether a prescriber in a specialty and geographic area is an outlier prescriber of opioids as compared to other prescribers of opioids within such specialty and area. ``(III) Exclusions.--The Secretary may exclude the following individuals and prescribers from the analysis under this clause: ``(aa) Individuals receiving hospice services. ``(bb) Individuals with a cancer diagnosis. ``(cc) Prescribers who are the subject of an investigation by the Centers for Medicare & Medicaid Services or the Office of Inspector General of the Department of Health and Human Services. ``(iii) Contents of notification.--The Secretary shall, based on input from stakeholders, specify the resources and other information to be included in notifications provided under clause (i). ``(iv) Modifications and expansions.-- ``(I) Frequency.--Beginning 5 years after the date of the enactment of this subparagraph, the Secretary may change the frequency of the notifications described in clause (i) based on stakeholder input. ``(II) Expansion to other prescriptions.--The Secretary may expand notifications under this subparagraph to include identifications and notifications with respect to concurrent prescriptions of covered Part D drugs used in combination with opioids that are considered to have adverse side effects when so used in such combination, as determined by the Secretary. ``(v) Opioids defined.--For purposes of this subparagraph, the term `opioids' has such meaning as specified by the Secretary through program instruction or otherwise.''.
summary: Commit to Opioid Medical Prescriber Accountability and Safety for Seniors Act or the COMPASS Act This bill requires the Centers for Medicare &amp; Medicaid Services (CMS) to identify outlier prescribers of opioids under the Medicare prescription drug benefit and Medicare Advantage prescription drug plans. Specifically, the CMS must: (1) establish an opioid-prescription threshold for determining whether a prescriber is an outlier compared to other prescribers, based on specialty and geographic area; (2) use National Provider Identifiers (unique provider identification numbers currently included on claims for covered drugs) to identify outlier prescribers; and (3) annually notify identified outlier prescribers of their status and provide them with resources on proper prescribing methods. The CMS may also identify and notify outlier prescribers based on co-prescriptions of covered drugs that have adverse effects when used in combination with opioids.